Argo Biopharma's siRNA Therapy Shows Promising Phase II Results for HAE
Event summary
- Argo Biopharma's Phase II interim data for BW-20805, an siRNA therapy for HAE, selected as late-breaking abstract for the 2026 AAAAI Annual Meeting.
- Study shows 100% reduction in HAE attack rate in the 600 mg Q24W group, 89% in the 300 mg Q24W group, and 87% in the 300 mg Q12W group.
- Plasma PKK levels reduced by up to 98% with sustained suppression observed over 169 days.
- BW-20805 demonstrated a favorable safety profile with mainly mild, transient injection-site reactions and no serious adverse events.
The big picture
Argo Biopharma's positive Phase II data for BW-20805 highlights the potential of siRNA therapeutics in treating rare genetic conditions like HAE. The results suggest a significant advancement in prophylactic treatments, addressing the current need for frequent dosing. The company's ability to sustain these results and navigate the regulatory pathway will be critical in determining BW-20805's market potential.
What we're watching
- Clinical Validation
- Whether the sustained PKK suppression and attack rate reduction can be maintained in larger, longer-term studies.
- Regulatory Pathway
- The pace at which Argo Biopharma can advance BW-20805 through Phase III trials and potential regulatory approval.
- Market Positioning
- How Argo Biopharma positions BW-20805 against existing HAE treatments, particularly in terms of dosing frequency and long-term efficacy.
Related topics